Apr 24 |
CureVac to cut costs in restructuring
|
Apr 23 |
CureVac BV FQ4 2023 Earnings Preview
|
Apr 23 |
CureVac N.V. (NASDAQ:CVAC) stock most popular amongst private equity firms who own 31%, while individual investors hold 30%
|
Apr 18 |
CureVac to Report Fourth Quarter and Full-Year 2023 Financial Results and Business Update on April 24, 2024
|
Apr 16 |
CureVac, MD Anderson team up for cancer vaccines
|
Apr 16 |
CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines
|
Apr 4 |
CureVac, GS Partner Release Data On Influenza Vaccine Study
|
Apr 4 |
CureVac posts early efficacy results for GSK-partnered flu shot
|
Apr 4 |
CureVac Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK
|